Cervicovaginal inflammation and HIV target cell activation in adolescent girls and young women with asymptomatic *Chlamydia trachomatis* infections

Smritee Dabee,[1,2]* Shaun Barnabas,[1,2]* Brian Kullin,[1,3] Bart Versteeg,[4] Nonhlanhla Mkhize,[5] Etienne Muller,[5] Venessa Maseko,[5] David A. Lewis,[6,7] Janan Dietrich,[8] Glenda Gray,[8,9] Katherine Gill,[1,3] Linda-Gail Bekker[1,3], Musalula Sinkala,[1] Darren P. Martin,[1] Sylvia M. Bruisten,[10,11] Heather B. Jaspan,[1,12,13] Jo-Ann S. Passmore[1,3,14#]

[1]Institute of Infectious Disease and Molecular Medicine (IDM), Division of Medical Virology, Dept. Pathology, University of Cape Town, Cape Town, South Africa; [2]Desmond Tutu HIV Centre, University of Cape Town, South Africa; [3]DST-NRF CAPRISA Centre of Excellence in HIV Prevention, University of Cape Town, Cape Town, South Africa; [4]Knowledge institute of the Dutch association of Medical Specialists, Utrecht, Netherlands; [5]Centre for HIV and STIs, National Institute for Communicable Disease, National Health Laboratory Service, South Africa; [6]Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, Australia; [7]Sydney Infectious Diseases Institute & Sydney Medical School-Westmead, University of Sydney, Sydney, Australia; [8]Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Diepkloof, Johannesburg, South Africa; [9]South African Medical Research Council, Cape Town, South Africa; [10]Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands; [11]Amsterdam Infection and Immunity Institute, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; [12]Seattle Children's Research Institute, Seattle, Washington, USA; [13]University of Washington, Seattle, Washington, USA; [14]National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa

#Address correspondence to Professor Jo-Ann S. Passmore, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Medical School, Anzio Road, Observatory, 7925 Cape Town, South Africa. E-mail: Jo-ann.Passmore@uct.ac.za, Tel: +27-21-650 7963

Word count: 2996; Abstract:279

Figures: 4; Tables: 1

Running title:
Persistent inflammation in adolescents with asymptomatic *Chlamydia trachomatis* [64 characters]

Abstract

Background: Adolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by *Chlamydia trachomatis* (CT) infections, a leading cause of pelvic inflammatory disease (PID), infertility, and increased HIV susceptibility. CT-induced genital inflammation disrupts mucosal barriers and activates HIV target cells, compounding reproductive and immunological risks. We investigated the impact of CT infection in AGYW from two South African regions, focusing on genital inflammation and immune activation.

Methods: An observational cohort of 298 sexually active AGYW (16–22 years) from Cape Town and Johannesburg was enrolled. Those in Johannesburg attended one visit while those in Cape Town were followed for three visits over 6-8 months. Cytokine profiling of cervicovaginal samples assessed inflammatory responses, while cervical cytobrush-derived CD4+ T cells were analyzed for CD38, Ki67 and CCR5 expression. CT *ompA* genotyping examined strain diversity.

Results: CT prevalence was 2.4 times higher in Cape Town (41.6%) than in Johannesburg (17.4%). Infection with CT led to an upregulation of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, with a stronger inflammatory response observed in Johannesburg. Genotypic analysis revealed regional variations: genovar D, which was predominant in Cape Town, was associated with lower IFN-γ levels, whereas genovar E, prevalent in Johannesburg, was linked to higher IFN-γ levels. AGYW who experienced CT infection across multiple study visits did not exhibit elevated genital tract cytokine levels compared to those with a single infection. However, they did show an increase in activated and proliferating cervical CD4+ T cells, which may contribute to heightened HIV susceptibility.

Conclusions: CT genotypic diversity and regional variations significantly influence immune responses in AGYW. Region-specific vaccines and integrated sexual health services would support mitigating STI and HIV risks in this vulnerable population.

Keywords: Adolescent girls and young women, AGYW, Chlamydia trachomatis, ompA, genital inflammation, Sexual and reproductive health

Introduction

Young women in sub-Saharan Africa face disproportionately high risks of HIV infection, driven by both biological and socio-behavioural vulnerabilities (1). Genital inflammation is a critical factor that significantly increases the risk of HIV acquisition (2), promotes the transmission of less fit HIV variants (3), and diminishes the efficacy of tenofovir-based topical microbicide for HIV prevention (4). Sexually transmitted infections (STIs), like *Chlamydia trachomatis* (CT)—the most prevalent bacterial STI globally, is a major driver of genital inflammation, even when clinically asymptomatic. CT infections without overt clinical signs or symptoms are common in women, leading to under-treatment despite its association with reproductive complications, including pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and increased HIV risk due to subclinical inflammation (5).

Although frequently asymptomatic (5), CT infection triggers genital cytokine responses that play a pivotal role in its pathogenesis (6). Pro-inflammatory mediators such as IL-1β, IL-6, and IP-10 are essential for immune cell recruitment but can also exacerbate tissue damage and increase HIV susceptibility by disrupting mucosal barriers and activating CD4+ T cells (7) (8) (2). Persistent CT infections intensify these inflammatory processes (8), with host-pathogen interactions during chronic infections promoting immune evasion strategies such as reduced antigen presentation and prolonged inflammation without clearance (8).

While significant research has explored CT pathogenesis, less attention has been given to the role of CT genotypic variation in shaping host immune responses and clinical outcomes. CT exhibits notable genetic diversity, particularly in the *ompA* gene, which encodes the major outer membrane protein (MOMP) (9). MOMP, a key structural and immunological determinant, is central to vaccine development efforts (10). Variations in *ompA* and other loci influence the bacterium's ability to evade immune defenses, induce

inflammation, and persist in host tissues (11), leading to strain-specific immune responses and variations in disease severity across populations.

Understanding genotypic variation is particularly relevant in high-burden regions like sub-Saharan Africa (11), where circulating CT strains may drive regional differences in inflammatory and immune activation patterns. Investigating these variations can help identify genotypes linked to heightened inflammatory responses and adverse outcomes, providing critical insights for vaccine design and targeted interventions.

Adolescent girls and young women (AGYW) are particularly vulnerable to CT infection (12) due to unique socio-behavioral, anatomical, and hormonal factors. The adolescent cervix features a larger area of ectropion (13), where the columnar epithelium of the endocervix is exposed to the vaginal environment. This anatomical characteristic creates a more accessible and permissive site for bacterial adhesion and invasion compared to the stratified squamous epithelium in mature women. Hormonal fluctuations during adolescence, including varying levels of estrogen and progesterone (14), further influence mucosal immunity by modulating cytokine production and immune responses (15). These factors, combined with the higher likelihood of asymptomatic infection, delayed treatment, and reinfection, contribute to the increased risk of prolonged inflammation, PID, tubal factor infertility, and ectopic pregnancy in AGYW compared to adults (16).

Given these challenges, it is critical to investigate the complex interplay between CT genotypes, host inflammatory responses, and mucosal immune activation in AGYW. This study aims to explore the immunological and inflammatory impact of CT infection in AGYW from two distinct South African regions, focusing specifically on how CT genotypes influence genital inflammation and immune activation.

Materials and Methods

Cohort description

Between November 2013 and February 2025, AGYW (16–22 years) were recruited from Cape Town and Johannesburg through the Desmond Tutu HIV Centre (DTHC) and the Perinatal HIV Research Unit (PHRU), respectively (17). Participants were excluded if they were HIV-positive, pregnant, sexually inactive, douched or used spermicides in the past two days, or took antibiotics in the past two weeks. AGYW using injectable contraceptives (DMPA/Net-EN) had visits two weeks post-injection, while non-users were scheduled during the luteal phase (days 14–28) of their menstrual cycle. Research Ethics Committees of the Universities of Cape Town and Witwatersrand approved the study (#267/2013 and #M130745, respectively). Written informed consent was obtained from participants 18+ years and assent was provided by those <18 years, with written consent from a parent/legal guardian.

Sample collection

At enrolment, participants completed a socio-demographic questionnaire covering ethnicity, language, sexual preference, reproductive health, and sexual behavior (17). At each visit, cervicovaginal fluid was collected using a Softcup® menstrual cup, inserted for one hour. During the clinical speculum exam, a Dacron vulvovaginal swab was taken for STI testing, a FLOQSwab™ collected lateral vaginal wall samples for Nugent scoring, and cervical mononuclear cells were obtained using a Digene® endocervical cytobrush.

Testing for STIs and bacterial vaginosis (BV)

Vulvovaginal samples were tested for discharge-causing STIs (CT, *Neisseria gonorrhoeae* [NG], *Trichomonas vaginalis* [TV], *Mycoplasma genitalium* [MG]), as well as ulcer-causing

STIs (HSV-1, HSV-2, *Haemophilus ducreyi* [HD], *Treponema pallidum)*, using real-time multiplex PCRs (18). BV was diagnosed by Nugent score: Nugent scores 7-10 were considered BV-positive, Nugent scores 4-6 were considered intermediate, and Nugent scores 0-3 were considered BV-negative. At both DTHC and PHRU, AGYW positive for CT were treated with Azithromycin (1g orally; single dose), those with NG given Ceftriaxone (250mg intramuscular injection; single dose), and those positive for BV (Nugent 7-10) or TV were given Metronidazole (400mg orally, twice daily; 7 days), according to South African national guidelines at the time. AGYW with CT or NG were given partner notification letters and referred to the local Department of Health clinic. At both DTHC and PHRU, AGYW diagnosed with CT were treated with a single oral dose of Azithromycin (1g), while those with NG received a single intramuscular injection of Ceftriaxone (250mg). For BV (Nugent score 7–10) or TV, treatment consisted of Metronidazole (400mg orally, twice daily for seven days), in accordance with South African national guidelines at the time. Additionally, AGYW diagnosed with CT or NG were provided with partner notification letters, referring them to the local Department of Health clinic for further management and partner treatment.

Chlamydia *ompA* genotyping

OmpA genovar diversity of CT was analyzed by MLST genotyping (19) (20). Sequence data were analysed using the CT database hosted on PubMLST (https://pubmlst.org/bigsdb?db=pubmlst_chlamydiales_seqdef). The *ompA* genovars were assigned by comparison to an offline reference database described previously (19) (20).

Measurement of cytokine concentrations

Luminex flow cytometry measured genital cytokine concentrations in cervicovaginal mucus collected via Softcup® (stored at -80°C and thawed) (21). Samples were filtered by centrifugation (1950g, 10 min, 4°C) using SPIN-X® 0.2µm filters to remove debris and prevent bead aggregation. Cytokine concentrations were measured using two kits: the Human Cytokine Group I 27-plex (FGF-basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, and VEGF) and the Human Cytokine 21-plex kit (IL-1α, IL-2RA, IL-3, IL-12(p40), IL-16, IL-18, CTACK, GRO-α, HGF, IFN-α2, LIF, MCP-3, M-CSF, MIF, MIG, NGF, SCF, SCGF-β, SDF-1α, TNF-β, and TRAIL) (Bio-Rad). Experiments followed manufacturer instructions. Detection limits ranged from 1-307 pg/ml, and concentrations were determined using 5PL regression. Values below detection limits were recorded as half the lowest measured concentration. IL-2, IL-5, and RANTES were reported as binary variables (presence/absence) since 76.0%, 64.2%, and 52.6% of their values were below detection limits.

Flow cytometry

CMC samples from Cape Town participants were collected and analyzed via flow cytometry at each visit. Cervical cytobrush samples were processed as previously described, with the

cell pellet resuspended in PBS, transferred to a 96-well plate, centrifuged at 1215g for 3 minutes at 4°C, and washed before staining.

An eight-color flow cytometry panel was used to assess HIV co-receptor CCR5 (APC; BD), activation markers CD38 (PE-Cy7; eBioscience) and HLA-DR (PE; BD), and proliferation marker Ki67 (FITC; BD) in CD4+ CD3+ T-cells. A dump channel (VIVID, CD14, CD19) excluded dead cells, B-cells, and monocytes. Cells were first incubated with the live/dead marker for 20 minutes at room temperature, washed twice, and stained with extracellular markers. After a 30-minute ice incubation, cells were washed and fixed using Cytofix/Cytoperm (BD). Following permeabilization, intracellular markers CD3 and Ki67 were added, and cells incubated for 30 minutes on ice. The pellet was resuspended in Cellfix, transferred to a FACS tube, wrapped in foil, and stored at 4°C until acquisition on the BD LSRFortessaTM. Data were acquired within 48 hours, with compensation tubes prepared for each run. FlowJo (v10.0.8; Treestar) was used for analysis, with gating based on FMO controls.

Statistical analysis

Statistical analyses and linear regressions were carried out using STATA 12.0 and R v3.6.0. Graphs and figures were generated using Prism 6 and R. The Mann-Whitney U-test was used to compare groups of continuous variables and two-sided Fisher's exact tests for categorical variables. For three or more groups, the Kruskal-Wallis one-way analysis of variance was used. Analyses were adjusted for multiple comparisons using false discovery rate step down procedures.

Results

A total of 298 sexually active AGYW (median age: 18 years; IQR: 17–20) from Cape Town and Johannesburg were included (21) (17). Johannesburg participants had a single-visit study, while Cape Town participants were followed over three visits spanning 6–8 months (Supplementary Table 1). More AGYW in Cape Town used hormonal contraception, whereas Johannesburg participants relied more on condoms. CT was the most prevalent STI (29.5%, 88/298), with higher prevalence in Cape Town (62/149 vs 26/149; $p<0.0001$). Among those with CT, 71.6% (63/88) had another STI or BV.

Impact of CT infection on genital inflammation in AGYW

The genital cytokine responses to CT infection in AGYW were assessed by multivariate linear regressions, adjusted for contraceptive use and co-infections (Figure 1A). AGYW infected with CT exhibited significant upregulation of cytokines across all functional classes compared to uninfected individuals. These included IL-1β (β-coefficient=0.36; p=0.022), IL-6 (β=0.21; p=0.038), TNF-α (β=0.23; p=0.015), IP-10 (β=0.29; p=0.035), MIG (β=0.27; p<0.0001), G-CSF (β=0.28; p=0.018), HGF (β=0.27; p=0.011), SCF (β=0.13; p=0.034), IFN-γ (β=0.17; p=0.025), and IL-4 (β=0.17; p=0.015), after adjusting for multiple comparisons. A focused analysis on cytokines implicated in CT pathogenesis (IL-1α, IL-1β, IL-6, IL-8, TNF-α, TNF-β) and protection (IFN-γ), including AGYW with CT infection alone (n=25; no co-infections or BV) compared to uninfected controls (n=61; no STIs or BV) (Figure 1B), further confirmed that CT infection significantly elevated concentrations of inflammatory cytokines, including IL-1α (p=0.03), IL-6 (p=0.01), IL-8 (p=0.05), IP-10 (p=0.002), and TNF-α (p=0.01). Although protective IFN-γ levels were higher in CT cases compared to controls, this difference was not significant.

Chlamydia diversity and associated inflammation by study site

CT infection was more inflammatory in Johannesburg than in Cape Town (Figure 2A). In Cape Town, CT was linked to MIG upregulation (not significant after multiple comparisons), while in Johannesburg, it upregulated 34/44 cytokines.. Among AGYW with CT alone (no other STIs or BV), inflammatory cytokines were higher in Johannesburg, with significant differences in IL-1β (p=0.007), IP-10 (p=0.05), and TNF-α (p=0.03) (Figure 2B).

To investigate whether CT strain diversity influenced inflammation, *ompA* genotyping was performed on 128 samples with available DNA (Figure 2C). This included 20/26 cases from Johannesburg and 108/121 cases from Cape Town, with 18 samples excluded due to low DNA or bacterial loads. The *ompA* genotypes differed significantly between the two sites (p=0.02; two-way ANOVA). In Cape Town, genovar D was most common (21%), while in Johannesburg, genovars E and G (23% each) dominated. Genovar G was more frequent in Johannesburg (23%) than in Cape Town (5%), whereas genovar F was absent in Johannesburg but found in 18% of Cape Town cases.

Cytokine profiles were varied by *ompA* genovar (Figure 2D). Genovar I, though rare, triggered the strongest inflammatory responses. Genovar D, prevalent in both Cape Town and Johannesburg, was linked to lower levels of protective IFN-γ compared to other genovars. More prevalent in Johannesburg than Cape Town, genovar G was associated with significantly lower levels of several cytokines across various classes than other genovars.

Inflammation associated with persistent CT infections

In Cape Town, where AGYW were followed longitudinally, 33.9% (43/127) were infected with CT at visit 2, and 18.2% (16/88) were infected at visit 3 (Table 1). Among these participants, 10 women were consistently infected with CT across all three study visits, 10 were infected during the first two visits only, and 5 were infected at visits 1 and 3 but not at

visit 2. To investigate whether persistent or repeat CT infections were associated with increased inflammation, cervicovaginal cytokine concentrations were compared among women infected at one, two, or three visits (Figure 3). The analysis revealed no significant differences in the concentrations of any measured cytokines across these groups, regardless of the duration of infection.

Genital tract HIV target-cell activation associated with CT infections

Cervical cytobrush-derived cells were used to assess the expression of CCR5 (HIV entry receptor on CD4+ cells), CD38 (a marker of cellular activation), and Ki67 (a marker of T-cell proliferation) on genital mucosal T cells (Cape Town only) (21). Figure 4A shows a representative figure of the gating strategy. The frequency of activated cervical $CD38^+$ cells among $CD4^+$ T cells was significantly higher in cases compared to controls, even after adjusting for multiple comparisons (p=0.05; Figure 4B, top panel). However, there were no significant differences in the frequencies of $CD4^+$ T cells or those expressing CCR5 or Ki67. Both cases and controls had higher numbers of total CD4+ T cells, activated ($CD38^+$), and proliferating ($Ki67^+$) $CD4^+$ T cells in cervical cytobrush samples.

Samples from AGYW infected with CT yielded significantly higher numbers of live cells (FACS events) for total T cells ($CD4^+CD3^+$; p=0.03), activated T cells ($CD38^+CD4^+CD3^+$; p=0.01), and proliferating T cells ($Ki67^+CD4^+CD3^+$; p=0.003) compared to controls. These findings suggest that CT infection is associated with increased presence of these cell subsets at the cervix (Figure 4B, bottom panel).

We further compared $CD4^+$ T cell events in women infected with CT at one, two, or three study visits (Figure 4C). The number of activated or proliferating cervical $CD4^+$ T cells did not differ significantly between women infected at multiple time points and those infected at a single visit. In a paired analysis of women infected at two study visits (n=32), there was

no significant difference in the number of cells (event counts) measured at the second visit compared to the first positive visit. This suggests that inflammation did not resolve or intensify with persistent or repeated infections (Figure 4C, lower panel).

Discussion

Understanding HIV risk in AGYW is essential for prevention strategies. This study examined how CT infection influences inflammatory cytokines and CD4+ HIV-target cell activation in cervicovaginal samples from AGYW in two South African communities. CT infection significantly upregulated inflammatory markers (IL-1β, IL-6, TNF-α, IP-10), with stronger responses in Johannesburg associated with the regional variation in *ompA* genotypes. Genovar D, prevalent in Cape Town, was associated with lower IFN-γ concentrations, while genovar E, more common in Johannesburg, was associated with higher IFN-γ levels. These findings underscore the importance of considering geographic and strain factors in the immunopathogenesis of CT (22) and their implications for vaccine development (23). Contrary to expectations, CT infections over multiple visits in Cape Town did not result in progressive inflammation, suggesting immune regulation. CT infection increased activated (CD38+), proliferating (Ki67+), and total CD4+ T cells, enhancing HIV susceptibility. While CCR5 expression was unchanged, its role in cell trafficking warrants further study.

Genotyping revealed significant differences in the distribution of *ompA* genovars between Cape Town and Johannesburg, with genovar D dominating in Cape Town and genovars E and G in Johannesburg. The association of genovar D with lower IFN-γ concentrations and genovar E with higher IFN-γ concentrations highlights the strain-dependent nature of CT immunogenicity. IFN-γ, secreted by immune cells, drives CT into a persistent state by inducing the expression of the enzyme indoleamine-2,3-dioxygenase (IDO) (28). Van Duynhoven et al. (29) found that reports of lower abdominal pain by symptomatic CT-infected women were more often associated with F or G group genotypes. These differences may reflect variation in immunodominant T cell epitopes within the major outer membrane protein (MOMP) (22) (9), further emphasizing the importance of strain characterization in understanding CT pathogenesis and guiding vaccine design.

This study has several limitations. Longitudinal data were only available from Cape Town, restricting the sample size for CT persistence analyses. Similarly, cellular activation assessments were limited to Cape Town, and CT-specific T cell responses were not measured. Such measurements could provide greater insight into the cellular sources of cervicovaginal cytokines and immune responses to CT infection. Additionally, our analysis focused on ompA genotyping, as the large number of STs identified by MLST genotyping resulted in too few representatives in each ST category for meaningful statistical comparisons. While ompA is highly immunodominant (22), it accounts for less than 1% of the CT genome (9), and recombination events in untyped regions (30) could not be ruled out. Partner treatment data were not systematically collected, as CT-positive cases were provided with partner notification slips, but follow-up was not conducted to confirm uptake. Furthermore, we did not perform post-treatment cure testing, making it impossible to distinguish between repeat and persistent infections. However, previous research suggests that over 80% of recurrent CT cases are due to reinfection by partners rather than persistence (31). Despite these limitations, the study provides valuable insights into the interplay between CT genetics, host immunity, and regional differences in inflammatory responses in AGYW, offering critical data for improved STI screening, treatment, and prevention strategies.

The high prevalence of CT and its persistent inflammation in AGYW underscores the need for improved STI screening and treatment programs in regions with high HIV burdens (12). Integrated sexual and reproductive health services should holistically address the dual risks of STIs and HIV in AGYW (32). Moreover, regional and strain-specific differences in CT immunogenicity highlight the importance of tailored prevention strategies, including region-specific vaccine development (23). Reducing STI burdens could significantly enhance HIV prevention and reproductive health outcomes.

In conclusion, this study provides novel insights into how CT infection influences genital immunity in AGYW, with significant implications for HIV risk. The findings highlight the role of strain diversity, regional variation, and co-infections in shaping inflammatory and immune responses. By elucidating these mechanisms, the study lays a foundation for more effective prevention strategies targeting STIs and HIV in adolescent populations, contributing to the broader goal of reducing HIV incidence and improving adolescent health.

Acknowledgements

We would like to thank the WISH study team, especially Ms Penelope Ngcobo (participant recruitment at DTHF), Sr Janine Nixon (sample collection at the University of Cape Town), and all the young women enrolled in the study. We also thank Ms Michelle Himschoot from GGD Amsterdam, who assisted with the MLST lab work. This research was funded by the EDCTP Strategic Primer grant (SP.2011.41304.038; PI J. Passmore, UCT) and a self-initiated grant from the South African Medical Research Council (2017-2020; PI J. Passmore, UCT).

References

1. de Oliveira T, Kharsany AB, Graf T, Cawood C, Khanyile D, Grobler A, et al. Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. Lancet HIV. 2017;4(1):e41-e50. Epub 20161201. doi: 10.1016/S2352-3018(16)30186-2. PubMed PMID: 27914874; PubMed Central PMCID: PMC5479933.
2. Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, et al. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis. 2015;61(2):260-9. Epub 20150421. doi: 10.1093/cid/civ298. PubMed PMID: 25900168; PubMed Central PMCID: PMC4565995.
3. Selhorst P, Masson L, Ismail SD, Samsunder N, Garrett N, Mansoor LE, et al. Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. Clin Infect Dis. 2017;64(1):79-82. Epub 20160929. doi: 10.1093/cid/ciw663. PubMed PMID: 27694480; PubMed Central PMCID: PMC5159604.
4. McKinnon LR, Liebenberg LJ, Yende-Zuma N, Archary D, Ngcapu S, Sivro A, et al. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nat Med. 2018;24(4):491-6. Epub 20180226. doi: 10.1038/nm.4506. PubMed PMID: 29480895; PubMed Central PMCID: PMC5893390.
5. Pillay J, Wingert A, MacGregor T, Gates M, Vandermeer B, Hartling L. Screening for chlamydia and/or gonorrhea in primary health care: systematic reviews on effectiveness and patient preferences. Syst Rev. 2021;10(1):118. Epub 20210419. doi: 10.1186/s13643-021-01658-w. PubMed PMID: 33879251; PubMed Central PMCID: PMC8056106.
6. Redgrove KA, McLaughlin EA. The Role of the Immune Response in Chlamydia trachomatis Infection of the Male Genital Tract: A Double-Edged Sword. Front Immunol. 2014;5:534. Epub 20141027. doi: 10.3389/fimmu.2014.00534. PubMed PMID: 25386180; PubMed Central PMCID: PMC4209867.
7. Arnold KB, Burgener A, Birse K, Romas L, Dunphy LJ, Shahabi K, et al. Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 2016;9(1):194-205. Epub 20150624. doi: 10.1038/mi.2015.51. PubMed PMID: 26104913.
8. Lijek RS, Helble JD, Olive AJ, Seiger KW, Starnbach MN. Pathology after Chlamydia trachomatis infection is driven by nonprotective immune cells that are distinct from protective populations. Proc Natl Acad Sci U S A. 2018;115(9):2216-21. Epub 20180209. doi: 10.1073/pnas.1711356115. PubMed PMID: 29440378; PubMed Central PMCID: PMC5834673.
9. Brunelle BW, Sensabaugh GF. The ompA gene in Chlamydia trachomatis differs in phylogeny and rate of evolution from other regions of the genome. Infect Immun. 2006;74(1):578-85. doi: 10.1128/IAI.74.1.578-585.2006. PubMed PMID: 16369014; PubMed Central PMCID: PMC1346613.
10. Olsen AW, Rosenkrands I, Holland MJ, Andersen P, Follmann F. A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars. NPJ Vaccines. 2021;6(1):58. Epub 20210419. doi: 10.1038/s41541-021-00312-9. PubMed PMID: 33875654; PubMed Central PMCID: PMC8055873.
11. Abdelsamed H, Peters J, Byrne GI. Genetic variation in Chlamydia trachomatis and their hosts: impact on disease severity and tissue tropism. Future Microbiol. 2013;8(9):1129-46. doi: 10.2217/fmb.13.80. PubMed PMID: 24020741; PubMed Central PMCID: PMC4009991.
12. Delany-Moretlwe S, Mgodi N, Bekker LG, Baeten JM, Li C, Donnell D, et al. High prevalence and incidence of gonorrhoea and chlamydia in young women eligible for HIV pre-exposure prophylaxis in South Africa and Zimbabwe: results from the HPTN 082 trial. Sex Transm Infect. 2023;99(7):433-9. Epub 20230308. doi: 10.1136/sextrans-2022-055696. PubMed PMID: 36889914; PubMed Central PMCID: PMC10555488.
13. Cagle AJ, Hu SY, Sellors JW, Bao YP, Lim JM, Li SM, et al. Use of an expanded gold standard to estimate the accuracy of colposcopy and visual inspection with acetic acid. Int J Cancer. 2010;126(1):156-61. doi: 10.1002/ijc.24719. PubMed PMID: 19585573.
14. Howard SR. Interpretation of reproductive hormones before, during and after the pubertal transition-Identifying health and disordered puberty. Clin Endocrinol (Oxf). 2021;95(5):702-15. Epub 20210808. doi: 10.1111/cen.14578. PubMed PMID: 34368982; PubMed Central PMCID: PMC9291332.
15. Dunbar B, Patel M, Fahey J, Wira C. Endocrine control of mucosal immunity in the female reproductive tract: impact of environmental disruptors. Mol Cell Endocrinol. 2012;354(1-2):85-93.

Epub 20120125. doi: 10.1016/j.mce.2012.01.002. PubMed PMID: 22289638; PubMed Central PMCID: PMC4332593.

16. Hoenderboom BM, van Benthem BHB, van Bergen J, Dukers-Muijrers N, Gotz HM, Hoebe C, et al. Relation between Chlamydia trachomatis infection and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in a Dutch cohort of women previously tested for chlamydia in a chlamydia screening trial. Sex Transm Infect. 2019;95(4):300-6. Epub 20190103. doi: 10.1136/sextrans-2018-053778. PubMed PMID: 30606817; PubMed Central PMCID: PMC6585279.
17. Barnabas SL, Dabee S, Passmore JS, Jaspan HB, Lewis DA, Jaumdally SZ, et al. Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. Int J STD AIDS. 2018;29(6):531-9. Epub 20171204. doi: 10.1177/0956462417740487. PubMed PMID: 29198180.
18. Lewis DA, Muller E, Steele L, Sternberg M, Radebe F, Lyall M, et al. Prevalence and associations of genital ulcer and urethral pathogens in men presenting with genital ulcer syndrome to primary health care clinics in South Africa. Sex Transm Dis. 2012;39(11):880-5. doi: 10.1097/OLQ.0b013e318269cf90. PubMed PMID: 23064538.
19. Versteeg B, Bruisten SM, van der Ende A, Pannekoek Y. Does typing of Chlamydia trachomatis using housekeeping multilocus sequence typing reveal different sexual networks among heterosexuals and men who have sex with men? BMC Infect Dis. 2016;16:162. Epub 20160418. doi: 10.1186/s12879-016-1486-2. PubMed PMID: 27090402; PubMed Central PMCID: PMC4836166.
20. Bom RJ, Christerson L, Schim van der Loeff MF, Coutinho RA, Herrmann B, Bruisten SM. Evaluation of high-resolution typing methods for Chlamydia trachomatis in samples from heterosexual couples. J Clin Microbiol. 2011;49(8):2844-53. Epub 20110608. doi: 10.1128/JCM.00128-11. PubMed PMID: 21653758; PubMed Central PMCID: PMC3147734.
21. Dabee S, Barnabas SL, Lennard KS, Jaumdally SZ, Gamieldien H, Balle C, et al. Defining characteristics of genital health in South African adolescent girls and young women at high risk for HIV infection. PLoS One. 2019;14(4):e0213975. Epub 20190404. doi: 10.1371/journal.pone.0213975. PubMed PMID: 30947260; PubMed Central PMCID: PMC6448899.
22. Su H, Morrison RP, Watkins NG, Caldwell HD. Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis. J Exp Med. 1990;172(1):203-12. doi: 10.1084/jem.172.1.203. PubMed PMID: 1694217; PubMed Central PMCID: PMC2188141.
23. Poston TB. Advances in vaccine development for Chlamydia trachomatis. Pathog Dis. 2024;82. doi: 10.1093/femspd/ftae017. PubMed PMID: 39043447; PubMed Central PMCID: PMC11338180.
24. Trent M, Bass D, Ness RB, Haggerty C. Recurrent PID, subsequent STI, and reproductive health outcomes: findings from the PID evaluation and clinical health (PEACH) study. Sex Transm Dis. 2011;38(9):879-81. doi: 10.1097/OLQ.0b013e31821f918c. PubMed PMID: 21844746; PubMed Central PMCID: PMC4425210.
25. Vickers DM, Osgood ND. The arrested immunity hypothesis in an immunoepidemiological model of Chlamydia transmission. Theor Popul Biol. 2014;93:52-62. Epub 20140207. doi: 10.1016/j.tpb.2014.01.005. PubMed PMID: 24513099.
26. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16(11):1201-10. doi: 10.1016/j.cellsig.2004.04.007. PubMed PMID: 15337520.
27. Olive AJ, Gondek DC, Starnbach MN. CXCR3 and CCR5 are both required for T cell-mediated protection against C. trachomatis infection in the murine genital mucosa. Mucosal Immunol. 2011;4(2):208-16. Epub 20100915. doi: 10.1038/mi.2010.58. PubMed PMID: 20844481; PubMed Central PMCID: PMC3010299.
28. Wong WF, Chambers JP, Gupta R, Arulanandam BP. Chlamydia and Its Many Ways of Escaping the Host Immune System. J Pathog. 2019;2019:8604958. Epub 20190806. doi: 10.1155/2019/8604958. PubMed PMID: 31467721; PubMed Central PMCID: PMC6699355.
29. van Duynhoven YT, Ossewaarde JM, Derksen-Nawrocki RP, van der Meijden WI, van de Laar MJ. Chlamydia trachomatis genotypes: correlation with clinical manifestations of infection and patients' characteristics. Clin Infect Dis. 1998;26(2):314-22. doi: 10.1086/516291. PubMed PMID: 9502448.
30. Harris SR, Clarke IN, Seth-Smith HM, Solomon AW, Cutcliffe LT, Marsh P, et al. Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat Genet. 2012;44(4):413-9, S1. Epub 20120311. doi: 10.1038/ng.2214. PubMed PMID: 22406642; PubMed Central PMCID: PMC3378690.

31. Batteiger BE, Tu W, Ofner S, Van Der Pol B, Stothard DR, Orr DP, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis. 2010;201(1):42-51. doi: 10.1086/648734. PubMed PMID: 19929379; PubMed Central PMCID: PMC2791188.
32. Kachale F, Mahaka I, Mhuriro F, Mugambi M, Murungu J, Ncube B, et al. Integration of HIV prevention and sexual and reproductive health in the era of anti-retroviral-based prevention: findings from assessments in Kenya, Malawi and Zimbabwe. Gates Open Res. 2021;5:145. Epub 20220328. doi: 10.12688/gatesopenres.13330.2. PubMed PMID: 37794965; PubMed Central PMCID: PMC10547113.

Supplementary Table 1. Characteristics for study participants

Characteristics	All women (n=298)	Johannesburg (n=149)	Cape Town Visit 1 (n=149)	Cape Town Visit 2 (n=128)	Cape Town Visit 3 (n=93)	p-value*
Age (years, range)	19 (18-20)	19 (17-20)	19 (18-19)	-	-	0.4
Condoms (always)	69/267 (25.8%)	49/138 (36%)	20/129 (16%)	-	-	0.0002
Condoms (last sex)	190/267 (71.2%)	94/138 (68%)	96/129 (74%)	-	-	0.3
Sex w HIV+ partner	20/267 (7.5%)	7/138 (5%)	13/129 (10%)	-	-	0.2
Transactional sex	1/267 (0.4%)	0/138 (0%)	1/129 (1%)	-	-	0.5
Contraceptive:						
None	14/298 (4.7%)	14/149 (9.4%)	0/149 (0%)	-	-	<0.0001
Condoms only	77/298 (31.9%)	77/149 (63.8%)	0/149 (0%)	-	-	<0.0001
COCP	16/298 (5.4%)	9/149 (6.0%)	7/149 (4.7%)	-	-	0.8
Implant	10/298 (3.4%)	1/149 (0.7%)	9/149 (6.0%)	-	-	0.02
Net-EN	129/298 (43.3%)	24/149 (16.1%)	105/149 (70.5%)	-	-	<0.0001
DMPA	38/298 (12.8%)	11/149 (7.4%)	27/149 (18.1%)	-	-	0.009
CCVR	1/298 (0.3%)	0/149 (0%)	1/149 (0.7%)	-	-	1.0
Ever pregnant	64/267 (24%)	30/138 (22%)	34/129 (26%)	-	-	0.4
Anal sex (ever)	11/267 (4.1%)	3/139 (2%)	8/129 (6%)	-	-	0.1
STI frequency:						
Any STI	221/298 (74.2%)	101/149 (67.8%)	120/149 (80.5%)	97/128 (75.8%)	70/93 (75.3%)	0.02
C. trachomatis	88/298 (29.5%)	26/149 (17.4%)	62/149 (41.6%)	43/127 (33.9%)	16/88 (18.2%)	<0.0001
N. gonorrhoea	24/298 (8.1%)	7/149 (4.7%)	17/149 (11.4%)	8/127 (6.3%)	7/88 (7.9%)	0.05
T. vaginalis	16/298 (5.4%)	5/149 (3.4%)	11/149 (7.4%)	10/127 (7.9%)	6/88 (6.8%)	0.2
M. genitalium	11/298 (3.7%)	5/149 (3.4%)	6/149 (4.0%)	7/127 (5.5%)	6/88 (6.8%)	1.000
Multiple STIs	30/298 (10.1%)	6/143 (4.0%)	24/149 (16.1%)	44/128 (34.4%)	23/88 (26.1%)	0.001
BV (Nugent 7-10)	135/292 (46.2%)	64/144 (44.4%)	71/148 (48.0%)	62/126 (49.2%)	39/84 (46.4%)	0.6
Any STIs+BV	111/298 (37.2%)	51/149 (34.2%)	60/149 (40.3%)	46/128 (35.9%)	31/93 (33.3%)	0.4

*Comparing Cape Town to Johannesburg prevalence; Chi-squared test. COCP: Combined oral contraceptive pill; DPMA: depot medroxyprogesterone acetate; Net-EN: norethisterone enanthate; STI: sexually transmitted infection; BV: bacterial vaginosis

Figure legends:

Figure 1. Impact of CT infection on cervicovaginal cytokine profiles in South African AGYW. (A) Multivariate linear regression analysis illustrating associations between cervicovaginal cytokine levels and CT infection status, adjusted for participant age, hormonal contraceptive use, and semen exposure. Each association is represented by a β-coefficient, with error bars indicating the 95% confidence intervals. Statistically significant associations ($p \leq 0.05$ after correction for multiple comparisons) are denoted with filled symbols. Cytokines are categorized by function: inflammatory (orange), chemokines (red), growth factors (blue), adaptive cytokines (green), and regulatory cytokines (purple). (B) Concentrations of cervicovaginal cytokines associated with inflammation (IL-1α, IL-1β, IL-6, IL-8, IP-10, TNF-α, TNF-β) and protection (IFN-γ) are compared between AGYW with CT infections (n = 26) and those without sexually transmitted infections (STIs) or bacterial vaginosis (BV) (n = 62). Group comparisons were performed using Mann-Whitney U-tests, with statistical significance set at $p \leq 0.05$ after adjustment for multiple comparisons.

Fig 2. Investigating the impact of CT genovar on inflammatory responses in AGYW from Cape Town and Johannesburg. (A) Multivariate linear regression analysis comparing cervicovaginal cytokine levels associated with CT infection in AGYW from Cape Town (left panel) and Johannesburg (right panel). The analysis is adjusted for participant age, hormonal contraceptive use, and semen exposure. Associations are represented by β-coefficients, with error bars indicating 95% confidence intervals. Statistically significant associations ($p \leq 0.05$ after correction for multiple comparisons) are marked with filled symbols. Cytokines are grouped by function: inflammatory (orange), chemokines (red), growth factors (blue), adaptive cytokines (green), and regulatory cytokines (purple). (B) Cervicovaginal cytokine concentrations associated with inflammation (IL-1α, IL-1β, IL-6, IL-8, IP-10, TNF-α, TNF-β) and protection (IFN-γ) are compared between AGYW with CT infections in Cape Town (CPT) and Johannesburg (JHB) (n = 26). Group comparisons were conducted using Mann-Whitney U-tests, with significance defined as $p \leq 0.05$ after adjustment for multiple comparisons. (C) Distribution of CT ompA genotypes in AGYW from Johannesburg (left pie chart) and Cape Town (right pie chart). Genovar D is represented in blue, E in green, F in yellow, G in orange, I in bright red, J in dark red, K in purple, and unknown genotypes in clear. (D) Multivariate linear regression analysis of associations between cervicovaginal cytokine levels and CT ompA genovars (D to K), adjusted for age, contraceptive use, and semen exposure. Associations are represented by β-coefficients with 95% confidence intervals. Statistically significant associations ($p \leq 0.05$ after correction) are marked with filled red symbols.

Figure 3. Cervicovaginal cytokine concentrations in AGYW infected with CT over one, two, or three study visits. Each dot represents the cytokine response of an individual participant, with black lines indicating the median values for each group. Group comparisons were conducted using Mann-Whitney U-tests, with statistical significance defined as $p \leq 0.05$.

Figure 4. Impact of prevalent or persistent CT Infections on cervical cytobrush-derived CD4+ T cell activation. (A) Representative gating strategy for flow cytometry analysis of cervical cytobrush-derived T cells, focusing on live CD4+CD3+ cells expressing activation marker CD38+, proliferation marker Ki67+, or HIV co-receptor CCR5. (B) The frequency (top panel) and absolute number of events (bottom panel) are shown for total CD4+CD3+ T cells (far left), CD4+CD3+ T cells expressing CD38 (middle left), CCR5 (middle right), and Ki67 (far right). Data were collected at visit 1 (study entry) from N = 36 controls and N = 18 CT cases. (C) Longitudinal analysis of cervicovaginal CD4+ T cell activation marker expression is presented for AGYW with CT infections spanning one, two, or three study visits (top panel). Matched analyses for participants with repeat CT infections across multiple visits are shown in the lower panel. Statistical comparisons were performed using Mann-Whitney U-tests, with significance defined as $p \leq 0.05$.



Figure 1A and 1B



Figure 2A and 2B


C
Johannesburg
12%
19%
4%
15%
23%
4%
23%
0%
Cape Town
16%
21%
3%
11%
18%
8%
5%
18%
D
E
F
G
I
J
K
Unknown

Figure 2C


D
Genovar:
D
E
F
G
I
J
K
Inflammatory
Chemokines
Growth factors
Adaptive
Regulatory
il1a
il1b
il6
il12p40
il12p70
il18
mif
tnfa
tnfb
trail
ctack
eotaxin
groa
il8
il16
ip10
mcp1
mcp3
mig
mip1a
mip1b
rantes
ifna2
bngf
fgfbasic
gcsf
gmcsf
hgf
il3
il7
il9
lif
mcsf
pdgfbb
scf
scgfb
sdf1a
vegf
ifng
il2
il4
il5
il13
il17
il2ra
il10
il1ra
n=32
n=27
n=19
n=10
n=9
n=20
n=4
Beta-coefficient

Figure 2D


IL-1a
IL-1b
IL-6
IL-6
IP-10
IFN-g
TNF-a
TNF-b
Cytokine concentration (pg/ml)
Number of study visits CT+

Figure 3


A
Singlets
FSC-H
FSC-A
Lymphocytes
SSC-A
FSC-A
Live CD3+
T-cells
Dump (VIVID/CD14
/CD19-PacBlue)
CD3-APC-H7
CD4+CD3+
T-cells
CD4-PerCP
-Cy5.5
CD8
CCR5 and
Ki67
CCR5-APC
Ki67-FITC
CD38 and
HLA-DR
CD38-PECy7
HLA-DR-PE

Figure 4A

B


Total
CD4+ T cells
CD38+
CD4+ T cells
CCR5+
CD4+ T cells
Ki67+
CD4+ T cells
CD4+ CD3+ Percentage
CD4+ CD3+ CD38+ Percentage
CD4+ CD3+ CCR5+ Percentage
CD4+ CD3+ Ki67+ Percentage
CD4+ CD3+ event counts
CD4+ CD3+ CD38+ event counts
CD4+ CD3+ CCR5+ event counts
CD4+ CD3+ Ki67+ event counts
p=0.05
p=0.03*
p=0.01
p=0.003
CT-
CT+

Figure 4B


CD4+ events
CD38+ events
Ki67+ events
CD4+ CD3+ event counts
CD4+ CD3+ CD38+ event counts
CD4+ CD3+ Ki67+ event counts
Number of visits CT+
V1
V2
Visit number

Figure 4C